-
Updated advice on use of nicorandil as second-line treatment for stable angina - some ulcers may progress to complications unless treatment is stopped.
-
Use a lower starting dose of thalidomide in patients with untreated multiple myeloma who are older than age 75 years.
-
In November, letters were sent regarding thalidomide, mycophenolate mofetil, nicorandil, InductOs, and dimethyl fumarate
-
Avoid concomitant use of amiodarone with simeprevir (Olysio▼) and sofosbuvir (Sovaldi▼) combination therapy, unless other antiarrhythmics cannot be given.
-
Patient reminder cards about the risk of osteonecrosis of the jaw are being introduced; denosumab 120 mg is now contraindicated in patients with unhealed lesions from dental or oral surgery.
-
EU review confirms that the cardiovascular risk of high-dose ibuprofen (≥2400mg/day) is similar to COX 2 inhibitors and diclofenac.
-
Avoid concomitant use of amiodarone with ledipasvir-sofosbuvir (Harvoni▼), and amiodarone with sofosbuvir (Sovaldi▼) and daclatasvir (Daklinza▼), unless other antiarrhythmics cannot be given.
-
New monitoring instructions to detect these side effects as soon as possible.
-
The new module helps clinicians understand how to identify, manage and avoid side effects when using corticosteroids.
-
While this defect is still being investigated, we remind you to always have a full spare cylinder loaded on the delivery device so the cylinders can be switched without delay.
-
Since November 2014, letters were sent regarding vismodegib (Erivedge ▼), chlorhexidine solutions, carbocisteine oral liquid (Mucodyne Paediatric 125mg/5ml), regadenoson (Rapiscan), a parenteral nutrition emulsion (Trio…
-
New advice to minimise risk
-
Reports of reconstituted solution leaking from some models of extension sets and pumps.
-
There have been reports of thrombotic microangiopathy and nephrotic syndrome linked to interferon beta treatment.
-
Emerging clinical trial evidence of increased cardiovascular risk.
-
New warnings due to risk of hyperkalaemia, hypotension, and impaired renal function have been agreed following an EU-wide review.
-
Statins (HMG-CoA reductase inhibitors) are widely used medicines for patients with lipid disorders and in the primary and secondary prevention of heart attack and stroke.
-
Patients with active infection with this virus should not be treated with ofatumumab.
-
New clinical trial information is available on the timing of the loading dose of prasugrel when used in patients with unstable angina or non-ST segment elevation myocardial infarction.
-
Reports of acquired haemophilia have been received in association with clopidogrel.
-
Use has been restricted to 48 hours’ maximum parenteral use under specialist supervision, after a European safety review.
-
Risk of serious haemorrhage—clarified contraindications apply to all 3 medicines.
-
Capillary leak syndrome (CLS) has been reported in recipients of filgrastim, including patients undergoing chemotherapy and a healthy donor undergoing peripheral blood progenitor-cell mobilisation; it has also been reported …
-
Codeine should only be used to relieve acute moderate pain in children older than 12 years and only if it cannot be relieved by other painkillers such as paracetamol or ibuprofen alone.
Furthermore, a significant risk of se…
-
-
New recommendations after a Europe-wide review of cardiovascular safety.
-
Remember to report any suspected adverse reactions
-
Indication restricted to second-line treatment and contraindicated with some cardiovascular conditions and medicines
Furthermore, cilostazol is now contraindicated in patients with any of the following:
Unstable ang…
-
Please be vigilant as life-threatening errors may occur
-
Risk of thrombosis and haemorrhage in patients with prosthetic heart valve(s) requiring anti-coagulant treatment.
-
Preliminary HPS2-THRIVE trial failed to show benefit outweighs risks
-
The non-identical nature of biological medicines and vaccines means it is very important that safety surveillance is carried out on a brand/product-specific basis.
-
The maximum recommended dose for simvastatin in conjunction with amlodipine and diltiazem is now 20 mg/day.
-
Levofloxacin (a fluoroquinolone antibiotic) is unfavourable as first-line treatment for several indications.
-
Updated contraindications and maximum dose recommendations when taken with a number of other medicines.
-
Contraindications clarified and reminder to monitor renal function.
-
New contraindications and warnings for combination of aliskiren (Rasilez) with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).
-
Healthcare professionals are reminded that chlorhexidine is known to induce hypersensitivity, including generalised allergic reactions and anaphylactic shock.
-
Statin use may be associated with a level of hyperglycaemia in some patients where formal diabetes care is appropriate.
-
Evidence does not support any increased risk of cancer in patients who use these medicines.
-
Healthcare professionals should consider the possibility of second primary malignancy in patients treated with lenalidomide.
-
Reminder that paediatric paracetamol liquids had been developed to ensure children receive optimum dosing for their age.
-
Following new evidence of cardiovascular, hepatic and pulmonary risk, a review of dronedarone has concluded that the benefits of treatment continue to outweigh the risks for the maintenance of sinus rhythm after successful c…
-
There is a risk of rhabdomyolysis if Systemic fusidic acid (Fucidin) is given with statins.
-
Use restricted to adults with advanced or metastatic breast cancer only.
-
Updated dosing for paediatric paracetamol liquids has been developed to ensure children receive the optimum dose for their age.
-
A reminder to healthcare professionals to fill out Yellow Card reports.
-
Healthcare professionals should be aware of this risk when prescribing prasugrel.
-
Dental examination and appropriate preventive dentistry should be considered before treatment with bevacizumab or sunitinib.
-
Sitaxentan (Thelin▼) withdrawn due to hepatotoxicity.